4D Molecular Therapeutics, Inc. - Common Stock - Bilanço (NASDAQ:FDMT) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

Toplam varlıklar 288.33 M353.49 M261.85 M339.89 M560.38 M566.71 M Toplam yükümlülükler 31.94 M34.38 M30.51 M32.06 M49.78 M61.05 M Toplam özsermaye 256.39 M319.11 M231.34 M307.83 M510.61 M505.66 M Toplam yükümlülükler ve hissedarların özsermayesi 288.33 M353.49 M261.85 M339.89 M560.38 M566.71 M Toplam borç —————— Net borç ——————

Haberler

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

electroCore (ECOR) Moves 7.1% Higher: Will This Strength Last?

Jefferies, 4D Molecular Therapeutics için hedef fiyatı düşürdü

RBC Capital, 4D Molecular hissesi için hedef fiyatı yükseltti

4D Molecular kazancı $0,96 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBC Capital, 4D Molecular hissesi için Outperform notunu 32 dolar hedefle yineliyor

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32